TR200101482T2 - WT1'e özgü imünoterapi için bileşimler - Google Patents

WT1'e özgü imünoterapi için bileşimler

Info

Publication number
TR200101482T2
TR200101482T2 TR2001/01482T TR200101482T TR200101482T2 TR 200101482 T2 TR200101482 T2 TR 200101482T2 TR 2001/01482 T TR2001/01482 T TR 2001/01482T TR 200101482 T TR200101482 T TR 200101482T TR 200101482 T2 TR200101482 T2 TR 200101482T2
Authority
TR
Turkey
Prior art keywords
compositions
polypeptide
specific immunotherapy
treatment
cell
Prior art date
Application number
TR2001/01482T
Other languages
English (en)
Inventor
Gaiger Alexander
Cheever Martin
Original Assignee
Corixa Corporation
Gaiger Alexander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corporation, Gaiger Alexander filed Critical Corixa Corporation
Publication of TR200101482T2 publication Critical patent/TR200101482T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Lösemi ve kanser gibi habis hastaliklarin tedavisi için bilesimler ve yöntemler tarif edilmektedir. Bilesimler bir WT1 polinükleotidi, bir WT1 polipeptidi, bir WT1 polipeptidi olusturan bir antijen olusturucu hücre, bir WT1 polipeptidine özel olarak baglanan bir antikor veya bir WT1 polipeptidi ile özel olarak tepkimeye girebilen bir T hücresinden bir veya daha fazlasini içerir. Bu tip bilesimler örnegin metastatik hastaliklarin önlenmesinde ve tedavi edilmesinde kullanilabilir.
TR2001/01482T 1998-09-30 1999-09-30 WT1'e özgü imünoterapi için bileşimler TR200101482T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25

Publications (1)

Publication Number Publication Date
TR200101482T2 true TR200101482T2 (tr) 2002-01-21

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01482T TR200101482T2 (tr) 1998-09-30 1999-09-30 WT1'e özgü imünoterapi için bileşimler

Country Status (25)

Country Link
EP (1) EP1117687B1 (tr)
JP (3) JP4243792B2 (tr)
KR (1) KR100752065B1 (tr)
CN (1) CN100486995C (tr)
AR (1) AR021849A1 (tr)
AT (1) ATE399179T1 (tr)
AU (1) AU6407899A (tr)
BR (1) BR9914116A (tr)
CA (1) CA2349442C (tr)
CZ (1) CZ20011144A3 (tr)
DE (1) DE69938970D1 (tr)
ES (1) ES2310052T3 (tr)
HK (1) HK1039782B (tr)
HU (1) HUP0103598A3 (tr)
IL (2) IL142216A0 (tr)
MX (1) MXPA01003344A (tr)
MY (1) MY139226A (tr)
NO (1) NO325839B1 (tr)
NZ (1) NZ510600A (tr)
PL (1) PL201881B1 (tr)
RU (1) RU2237674C2 (tr)
SA (1) SA00200872B1 (tr)
TR (1) TR200101482T2 (tr)
TW (1) TWI285648B (tr)
WO (1) WO2000018795A2 (tr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) * 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
ES2298353T3 (es) * 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
CN1320923C (zh) * 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
EP1584627B1 (en) * 2003-01-15 2009-10-07 International Institute of Cancer Immunology, Inc. Dimerized peptide
KR101431312B1 (ko) * 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
ES2587980T3 (es) 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
DK2091965T3 (da) * 2006-10-17 2013-08-05 Oncotherapy Science Inc Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
CA2670658A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2009009168A (es) 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
EP2125868B1 (en) * 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
ES2679127T3 (es) * 2007-12-05 2018-08-22 International Institute Of Cancer Immunology, Inc. Composición vacunal contra el cáncer
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
ES2731343T3 (es) * 2009-05-19 2019-11-15 Univ Miami Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
EP2868325B1 (en) 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
AU2014266396A1 (en) * 2013-05-13 2015-12-03 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
MX392470B (es) * 2014-12-11 2025-03-24 Int Inst Cancer Immunology Inc Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
KR20180048992A (ko) * 2015-09-10 2018-05-10 메모리얼 슬로안-케터링 캔서 센터 T 세포 요법에 의해 다발성 골수종 및 형질 세포성 백혈병을 치료하는 방법
LT3377516T (lt) * 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
SG11202005632SA (en) 2017-12-21 2020-07-29 Hoffmann La Roche Antibodies binding to hla-a2/wt1
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
MX2021003660A (es) 2018-09-28 2021-05-28 Sumitomo Pharma Co Ltd Composicion inyectable.
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2021230247A1 (ja) 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
AU2022327884A1 (en) 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer
CN118076378A (zh) * 2021-09-24 2024-05-24 株式会社车疫苗研究所 包含肿瘤相关抗原衍生肽以及由脂肽和免疫活性物质组成的佐剂的抗癌疫苗组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原

Also Published As

Publication number Publication date
PL201881B1 (pl) 2009-05-29
EP1117687B1 (en) 2008-06-25
NO20011613L (no) 2001-05-29
MY139226A (en) 2009-08-28
NO20011613D0 (no) 2001-03-29
HUP0103598A3 (en) 2005-11-28
ES2310052T3 (es) 2008-12-16
HK1039782B (en) 2008-11-14
AR021849A1 (es) 2002-08-07
BR9914116A (pt) 2002-01-15
AU6407899A (en) 2000-04-17
IL142216A0 (en) 2002-03-10
RU2237674C2 (ru) 2004-10-10
PL348595A1 (en) 2002-06-03
CZ20011144A3 (cs) 2002-06-12
WO2000018795A9 (en) 2000-08-31
CN100486995C (zh) 2009-05-13
JP4235984B2 (ja) 2009-03-11
ATE399179T1 (de) 2008-07-15
MXPA01003344A (es) 2004-04-21
HUP0103598A2 (hu) 2002-01-28
CN1336935A (zh) 2002-02-20
JP4243792B2 (ja) 2009-03-25
NZ510600A (en) 2003-12-19
JP2007001984A (ja) 2007-01-11
NO325839B1 (no) 2008-07-28
TW200606176A (en) 2006-02-16
DE69938970D1 (de) 2008-08-07
EP1117687A2 (en) 2001-07-25
KR100752065B1 (ko) 2007-08-28
WO2000018795A3 (en) 2000-10-26
JP2008069172A (ja) 2008-03-27
TWI285648B (en) 2007-08-21
SA00200872B1 (ar) 2007-01-30
CA2349442C (en) 2012-12-04
KR20010085861A (ko) 2001-09-07
HK1039782A1 (en) 2002-05-10
CA2349442A1 (en) 2000-04-06
WO2000018795A2 (en) 2000-04-06
JP2002525099A (ja) 2002-08-13
IL142216A (en) 2009-06-15

Similar Documents

Publication Publication Date Title
TR200101482T2 (tr) WT1'e özgü imünoterapi için bileşimler
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
TR200200937T2 (tr) Yumurtalık kanseri tedavisi için bileşimler.
TR200003087T2 (tr) Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
PT724456E (pt) Anticorpos contra cd4
TR199902956T2 (tr) Pozisyonlar 5 ve 6 içinde degistirilmis olan GnRH antagonistleri.
ATE335814T1 (de) Modifizierte arginindeaminase
DK0556310T3 (da) Quinazolinderivater til forhøjelse af antitumoraktivitet
TR200000115T2 (tr) Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler.
DE69128543D1 (de) Monoklonale antikörper der maus
TR200001023T2 (tr) Alfa-aril-N-Alkilnitronlar ve onları içeren farmasötik kompozisyonlar.
NO963918L (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
BG101024A (bg) Моноклонално антитяло срещу сd44v6
TR200100462T2 (tr) Muskarinik agonistleri ve antagonistleri
MX9301083A (es) Complejos de quelato y procesos para su preparacion.
DE69021742D1 (de) Verfahren zum Nachweis von kleinzelligem Carzinom und die Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren, für diesen zweck.
DE60043942D1 (de) Fluoreszierende cobalamine und deren verwendung
ATE180489T1 (de) Für leberzellkarzinom spezifisches onkogen
ATE285247T1 (de) Krebstherapie mit lymphotoxin
TR200002269T2 (tr) Katı yakıt katkıları.